Similar articles

• Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.

  Cluzeau T, Loschi M, Fenaux P, Komrokji R, Sallman DA. Cluzeau T, et al. Int J Mol Sci. 2021 Sep 18;22(18):10105. doi: 10.3390/ijms221810105. Int J Mol Sci. 2021. PMID: 34576266 Free PMC article. Review.
• Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

  Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S. Maslah N, et al. Haematologica. 2020 Jun;105(6):1539-1551. doi: 10.3324/haematol.2019.218453. Epub 2019 Sep 5. Haematologica. 2020. PMID: 31488557 Free PMC article.
• What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?

  Wang C, Sallman DA. Wang C, et al. Cancer J. 2022 Jan-Feb 01;28(1):51-61. doi: 10.1097/PPO.0000000000000569. Cancer J. 2022. PMID: 35072374 Review.
• Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.

  Patel SA, Lloyd MR, Cerny J, Shi Q, Simin K, Ediriwickrema A, Hutchinson L, Miron PM, Higgins AW, Ramanathan M, Gerber JM. Patel SA, et al. Leuk Lymphoma. 2021 Dec;62(14):3348-3360. doi: 10.1080/10428194.2021.1957869. Epub 2021 Sep 9. Leuk Lymphoma. 2021. PMID: 34496723
• Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

  Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E. Möllgård L, et al. Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669. Haematologica. 2011. PMID: 21719884 Free PMC article. Clinical Trial.